Abstract Metastatic non-small cell lung cancer remains a disease with a high annual incidence and annual mortality worldwide, with limitations in first-line treatment past a fixed amount of platinum doublet chemotherapy for patients that do not harbor a targetable genetic abnormality such as an EGFR mutation or ALK gene rearrangement. Previous attempts to extend first-line treatment past 4-6 cycles of conventional cytotoxic chemotherapy have been disappointing, resulting in diminished quality of life and increased toxicity without improvement of progression-free or overall survival. Several advances in third-generation chemotherapy and targeted agents have generated a renewed interest in maintenance therapy, with several randomized phase III trials reporting a significant improvement in progression-free and overall survival with manageable toxicity profiles. The availability of new chemotherapy agents, tyrosine kinase inhibitors, and immunotherapy agents with a more tolerable or nonoverlapping toxicity profile have resulted in improvements in progression-free survival and median overall survival in maintenance settings with specific agents such as pemetrexed and erlotinib. Patients who are responding to first-line therapy, have not suffered a detrimental decrease in quality of life or performance status, and understand the risks and benefits of further immediate chemotherapy should be considered for maintenance treatment.
Introduction
Non-small cell lung cancer (NSCLC) remains one of the most commonly diagnosed and lethal malignancies, accounting for 15-17 % of new cancer diagnoses, of which 56 % are metastatic at the time of diagnosis [1] [2] [3] . Despite recent advances in therapy and different treatment approaches based on histologic molecular subtypes, initial chemotherapy with a platinum doublet remains the standard of care for patients with metastatic disease that do not harbor a targetable mutation [4] . A standard approach is to employ a ''watch and wait'' approach after the completion of 4-6 cycles of first-line chemotherapy, and this is advocated by multiple guidelines [5] [6] [7] . However, this approach is often met with anxiety by patients and providers. Recent breakthroughs in tyrosine kinase inhibitors (TKI) for metastatic NSCLC that harbors epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements have rekindled the desire to offer safe, tolerable continuation of therapy to all NSCLC patients, as these agents are commonly administered with no fixed cycle length and are discontinued only when progression or unacceptable toxicity occurs [8] [9] [10] . Furthermore, while there are now several viable second-line therapeutic options, only approximately 50-60 % of patients in retrospective reviews and clinical trials receive second-line therapy, most often due to declining performance status [11] [12] [13] [14] . These concerns have led to multiple attempts to extend the number of cycles given prior to progression-an approach typically referred to as ''maintenance'' therapy. Until recently, there has been little high-level clinical evidence to justify the routine use of maintenance therapy.
Maintenance strategies in NSCLC are generally categorized as either ''continuous'' or ''switch.'' Continuous maintenance is defined as continued administration of one or more drugs in the first-line setting past 4-6 cycles until progressive disease or limiting toxicity. Switch maintenance is defined as consecutive administration of secondline chemotherapeutic agents after the completion of 4-6 cycles of first-line chemotherapy. For the purpose of this article, relevant phase II and phase III studies were identified by searching PubMed and Embase up to October 2012 without language restriction. The search was performed using the keywords ''NSCLC,'' ''non-small-cell lung cancer,'' ''maintenance,'' ''consolidation,'' and ''early second-line.'' This search was supplemented by a manual search of the annual meeting proceedings of the American Society of Clinical Oncology. Key phase III studies and meta-analyses that address the role of maintenance treatment of patients with NSCLC were cross-referenced in order to identify all relevant trials. The aim of this review is to provide an historical perspective of how maintenance strategies have evolved, review the most recent data addressing maintenance therapy in NSCLC, and identify clinical trials in process, with particular emphasis placed on larger phase III trials that offer comparisons of maintenance therapy to best supportive care or placebo arms.
Continuation Maintenance Therapy

Continuation Maintenance: Conventional Chemotherapy
The concept of continuation maintenance was evaluated in its earliest forms when defining established parameters for the duration of therapy in the first-line setting, and was initially evaluated by comparing two different predetermined cycle numbers. The first such trial was conducted before platinum doublet therapy was established as the standard of care, by randomizing stage IIIB/IV NSCLC patients to 3 versus (vs.) 6 cycles of mitomycin, vinblastine, and cisplatin (MVP) [15] . In this study of 308 patients, the study failed to demonstrate a statistically significant improvement in 6 vs. 3 cycles of therapy: median time to disease progression (TTP) was 5 months in each arm, with a median overall survival (OS) of 6 months in the 3-cycle arm vs. 7 months in the 6-cycle arm (p = 0.2). Notably, only 31 % of the patients randomized to the 6-cycle arm were able to complete the scheduled course of therapy, with significant incremental increases of grade 3/4 hematologic and non-hematologic toxicities in the 6-cycle arm. Quality of life (QoL) parameters did not differ between the two groups during the initial phase of treatment, but began to diverge after 9 weeks of therapy, with a significant difference in fatigue (p = 0.03) and a trend toward increased grade 3 neutropenia (p = 0.06) in the 6-cycle arm. von Plessen et al. [16] investigated the treatment of IIIB/IV NSCLC with 3 vs. 6 cycles of carboplatin plus vinorelbine with primary endpoints of OS and QoL. Again, there was a non-significant trend towards improvements in the median OS of 28 vs. 32 weeks (p = 0.75) and median progression-free survival (PFS) of 16 vs. 21 weeks (p = 0.21) in the 3-vs. 6-cycle arm, with no significant difference in QoL parameters. Seventy-eight percent of patients completed 3 cycles, as compared to 54 % of patients who completed 6 cycles. Treatment duration with modern platinum doublet chemotherapy regimens was addressed by Park et al. [17] , who conducted a phase III trial designed to determine if increasing the number of predefined cycles translated into a clinical benefit. Patients who demonstrated disease control-defined as stable disease (SD), partial response (PR), or complete response (CR) by computed tomography (CT) scan-following 2 cycles of cisplatin plus paclitaxel, docetaxel, or gemcitabine chemotherapy were randomized to two or four additional cycles of chemotherapy with the same agents. The trial met its primary endpoint of noninferiority between the two arms with a median TTP of 6.2 months for 6 chemotherapy cycles as compared with 4.6 months for 4 cycles (p = 0.0001). There was no statistically significant difference in OS, with a median duration of 14.9 months in the 4-cycle arm and 15.9 months in the 6-cycle arm (p = 0.461). A higher percentage of patients in the 4-cycle arm compared to the 6-cycle arm (74.4 vs. 62.7 %; p = 0.026) were able to proceed to second-line therapy, providing a potential reason why TTP differences did not translate into an OS benefit in this trial. While QoL parameters were not directly addressed in this study, hematologic and nonhematologic treatment related adverse events (AEs) were similar between the two groups.
Continuation maintenance of a platinum doublet until disease progression was first investigated by Socinski et al. [18] , who randomized patients to 4 cycles of carboplatin plus paclitaxel every 3 weeks vs. continuation of doublet therapy until disease progression or toxicity with co-primary endpoints of OS and QoL. Both cohorts received second-line single-agent paclitaxel at the time of radiographic progression, and 42 % of patients in the continuation arm received more than 4 cycles, with only 45 % of patients proceeding to second-line therapy. There was no statistically significant difference in OS between the two arms: 6.6 months in the non-continuation arm and 8.5 months in the continuation arm (p = 0.63), with similar overall response rates (ORR) of 22 vs. 24 % (p = 0.80). There were no statistical differences in QoL measurements, and while rates of hematologic toxicity were similar, the rate of grade 2 or greater neuropathy increased from 19.9 % at the fourth cycle of treatment to 43 % by cycle 8. In summary, these trials evaluating the continuation of chemotherapy with modern platinum-based doublets [16] [17] [18] or older regimens [15] have frequently demonstrated increased toxicity without significant clinical benefits in OS, PFS, and QoL parameters, which have in part led to consensus guidelines restricting platinum doublet chemotherapy to 4-6 cycles [5, 6, 19] .
More recent continuation maintenance trials employing platinum doublets have investigated limiting the platinumbased agent to the more conventional 4-6 cycles and continuation of the non-platinum agent until progression or dose-limiting toxicity. Several earlier trials were designed to allow for the continuation of single-agent gemcitabine after initial gemcitabine plus platinum first-line therapy. Brodowicz et al. [20] performed a phase III trial where 352 patients were randomized (2:1) after 4 cycles of cisplatin plus gemcitabine first-line therapy to gemcitabine continuation vs. best supportive care (BSC) with a primary endpoint of TTP. TTP favored the gemcitabine arm (6.6 vs. 5 months; p \ 0.001), which again did not translate into a median OS difference (13.0 months for continuation gemcitabine vs. 11.0 months for BSC arms; p = 0.195). Similar percentages of patients (56.6 vs. 57.1 %) went on to receive second-line therapy in the two arms. Belani et al. [21] enrolled 519 patients in a phase III trial where NSCLC patients receiving first-line carboplatin plus gemcitabine were randomized 1:1 to gemcitabine vs. BSC with a primary endpoint of OS. There was no significant difference in median PFS between the two groups (3.9 months for gemcitabine vs. 3.8 months for BSC; p = 0.575), and no statistically significant difference in median OS (9.3 months for gemcitabine vs. 8.0 months for BSC; p = 0.838; HR 0.97; 95 % CI 0.72-1.30). There was a higher incidence of grade 3/4 hematologic toxicity (anemia 9.4 vs. 2.4 %; neutropenia 13.3 vs. 1.6 %; thrombocytopenia 9.4 vs. 1.4 %) and non-hematologic (fatigue 3.9 vs. 1.6 %) toxicity in the maintenance gemcitabine arm. Perol et al. [22] conducted a phase III trial that randomized 464 NSCLC patients without progressive disease after 4 cycles of gemcitabine and cisplatin first-line therapy in a 1:1:1 fashion to maintenance gemcitabine, erlotinib, or BSC, with a primary endpoint of PFS. Median PFS was 3.8, 2.9, and 1.9 in the gemcitabine, erlotinib, and BSC arms, respectively. PFS in both the gemcitabine (HR 0.56; 95 % CI 0.44-0.72; p \ 0.001) and erlotinib (HR 0.69; 95 % CI 0.54-0.88; p = 0.003) continuation maintenance were statistically significant when compared to BSC. Again, no significant median OS benefit (12.1 vs. 10.8 months; p = 0.3867) was seen for gemcitabine maintenance, with a 25 % absolute increase in grade 3/4 treatment related AEs over observation alone (27.9 vs. 2.6 %, respectively). Importantly, second-line therapy with pemetrexed was prespecified and a high proportion of the patients in each arm received this therapy (BSC, 90.9 %; gemcitabine, 77.2 %; erlotinib, 79.9 %). Given the lack of any identified differences in OS, gemcitabine does not currently have Federal Drug Administration (FDA) or European Medicines Agency (EMA) approval for maintenance therapy in NSCLC.
To date, there have been two studies that have evaluated paclitaxel continuation maintenance after first-line carboplatin plus paclitaxel, both of which were published by Belani et al. [23, 24] . In the first study, 309 patients were treated with three different carboplatin/paclitaxel regimens for 16 weeks in total. One hundred thirty responding patients after 16 weeks of therapy were randomized (1:1) to weekly paclitaxel or observation with a primary endpoint of TTP. Although underpowered, there was a trend towards an increase in TTP with weekly paclitaxel (38 weeks) vs. observation (29 weeks) . There was also a trend towards OS in the weekly paclitaxel arm (75 weeks) vs. observation (60 weeks). An additional phase III trial by the same lead author randomized 444 patients at the time of treatment initiation to 4 cycles of carboplatin/weekly paclitaxel regimen vs. 4 cycles of carboplatin/paclitaxel administered every 3 weeks with a primary endpoint of OS. Patients with SD or response (n = 141) were eligible to continue treatment with weekly paclitaxel until disease progression. TTP was 33 weeks in the weekly paclitaxel arm, 29 weeks in the 3-weekly paclitaxel arm, and 11 and 12 weeks, respectively, for patients who were ineligible for (n = 261) or opted not to receive (n = 42) maintenance therapy. There was no formal BSC or placebo arm for the maintenance portion of this trial, with approximately 70 % of patients in each arm receiving maintenance chemotherapy. It is also important to note that both of the trials mentioned above were designed to compare the efficacy and safety of the different weekly paclitaxel regimens, and were not specifically designed to address the efficacy of continuation maintenance paclitaxel, as neither trial was sufficiently powered to detect a difference in maintenance therapy or were randomized at the start of maintenance therapy.
Pemetrexed is currently FDA and EMA approved for ''switch'' maintenance therapy, and is currently restricted to patients with nonsquamous histology. The histology restriction is partly based upon this agent's differential efficacy in nonsquamous histology, as originally demonstrated in phase III registration trials [14, 25] , with particular efficacy seen in patients with adenocarcinoma histology [26] . The drug's role in continuation maintenance therapy has been studied in the PARAMOUNT trial by Paz-Ares et al. [27] . Five hundred thirty-nine patients with nonsquamous histology were randomized (2:1) after stable disease or response to 4 cycles of cisplatin and pemetrexed to continuation of pemetrexed every 3 weeks until disease progression or BSC plus placebo with a primary endpoint of PFS and secondary endpoints of patient reported outcomes, resource use, response rate, and OS [27, 28] . All patients received supplementary vitamin B 12 injections, folic acid, and dexamethasone. Patients on pemetrexed continuation maintenance (n = 359) had a significant improvement in PFS of 4.1 months, as compared to 2.8 months (HR 0.60; 95 % CI 0.5-0.73; p \ 0.0001). Grade 3/4 treatment-related AEs were higher in the pemetrexed group when compared to the placebo, with the most common being fatigue (4.7 vs. 1.1 %; p \ 0.05), anemia (6.4 vs. 0.6 %; p \ 0.05), and neutropenia (5.8 vs. 0 %; p \ 0.05). Preplanned analysis assessing the duration of pemetrexed continuation maintenance therapy ([6 vs. \6 cycles) demonstrated no difference in the amount and severity of grade 3/4 AEs, with the exception of neutropenia (8 vs. 2 %, respectively; p = 0.015). There was no difference in QoL parameters between the intervention and placebo arms that were identified during the induction or maintenance portions of therapy. The PARAMOUNT authors presented an update on secondary trial outcomes including OS at the 2012 ASCO Annual Meeting [28] . Pemetrexed continuation resulted in a 22 % reduction in death, with a median OS from the time of randomization of 13.9 vs. 11.0 months in placebo plus BSC (HR 0.78; 95 % CI 0.64-0.96; p = 0.0195). The difference in OS persisted when evaluated from the time of doublet therapy induction (16.9 vs. 14 months; HR 0.78; 95 % CI 0.64-0.96; p = 0.0191). The percentages of the pemetrexed maintenance patients who were alive at 12 and 24 months were 58 and 32 %, respectively, as compared to 45 and 21 % in the placebo plus BSC cohort. A majority of the patients on continuation maintenance pemetrexed were able to proceed with second-line therapy, with 64 % of the patients receiving post-discontinuation therapy in the pemetrexed continuation arm versus 72 % of patients in the BSC arm. Continuation of pemetrexed likely confers a clinical benefit in NSCLC partly because it is very well tolerated with minimal grade 3/4 AEs, even during long-term use.
Continuation Maintenance: Targeted Therapies
Bevacizumab, a humanized monoclonal antibody against the VEGFA ligand, has been evaluated in multiple trials and is a common continuation maintenance agent used in practice today. The initial phase III trial, Eastern Cooperative Oncology Group (ECOG) 4599, was conducted by Sandler et al. [12] , who randomized 878 NSCLC patients to paclitaxel plus carboplatin every 3 weeks for 6 cycles with or with bevacizumab at a dose of 15 mg/kg, with a primary endpoint of OS. It is worth noting that patients with squamous cell histology, a history of therapeutic anticoagulation, hemoptysis, or brain metastasis were excluded based upon the occurrence of fatal hemorrhagic events during a prior phase II study of bevacizumab in this population [29] . Patients that responded to or had stable disease on doublet therapy plus bevacizumab continued bevacizumab as a single agent. Patients randomized to the bevacizumab arm had a higher median OS (12. There were 15 treatment-related deaths in the bevacizumab arm vs. 2 in the standard of care arm, which included 5 deaths due to hemoptysis and 2 due to hematemesis. The rate of at least one grade 3 or worse event was statistically higher in the cohort of patients 70 and older (87 vs. 61 %; p \ 0.001) [30] . Additional retrospective analysis revealed that patients who developed hypertension had a lower HR for death and improved PFS [31] . Yet another retrospective analysis of phase II/III data revealed that tumor cavitation at baseline was predictive for the pulmonary hemorrhage recorded in both trials [32] .
The AVAIL (AVAstin In Lung cancer) trial performed by Reck et al. [33] randomized 1,043 NSCLC patients with nonsquamous histology to placebo, bevacizumab 7.5 mg/kg, and bevacizumab 15 mg/kg combined with cisplatin and gemcitabine (1,250 mg/m 2 ) for up to 6 cycles. Patients with stable or responsive disease on either bevacizumab arm were able to continue with the bevacizumab every 3 weeks until disease progression or toxicity. The primary endpoint was amended from OS to PFS, and the trial was not powered to detect a difference between the two bevacizumab doses. The median PFS was significantly higher for both treatment arms: 6.1 vs. 6.7 months (p = 0.003) vs. 6.5 months (p = 0.03) in the placebo, low-dose bevacizumab, and high-dose bevacizumab arms, respectively, with similar AE rates among all treatment arms including hemorrhage (\1.5 %), despite the inclusion of a small group of patients on therapeutic anticoagulation (9 %).
Recently, the PointBreak investigators published the results of their phase III trial, in which a maintenance approach with pemetrexed and the anti-VEGF ligand monoclonal antibody bevacizumab was employed. This trial was proposed after phase II data where 50 patients with nonsquamous histology were enrolled in an singlearm open-label trial to receive carboplatin, pemetrexed, and bevacizumab at a 15 mg/kg dose every 3 weeks for 6 cycles, followed by continuation of both pemetrexed and bevacizumab in patients with stable or responding disease until dose-limiting toxicity or progression [34] . ORR was 55 %, with a PFS of 7.8 months and an OS of 14.1. In the phase III setting, nonsquamous patients were randomized to pemetrexed, carboplatin, plus bevacizumab (arm 1, n = 472), with combined continuation maintenance therapy with pemetrexed and bevacizumab given to patients without disease progression (n = 292), or to paclitaxel, carboplatin, plus bevacizumab (arm 2, n = 467), with continuation maintenance bevacizumab for patients without disease progression (n = 298) [35] . PFS from the time of randomization was 6 vs. 5.6 months in arm 1 vs. arm 2 (HR 0.83; 95 % CI 0.71-0.96; p = 0.012), with an OS difference of 13.4 vs. 12.6 months that was not statistically significant (HR 1.0; 95 % CI 0.86-1.16; p = 0.949). In a preplanned analysis addressing the maintenance components of the trial, the PFS was 8.6 months in arm 1 and 6.9 months in arm 2, with an OS of 17.7 vs. 15.7 months, respectively (p values not provided). There were highergrade 3/4 hematologic AEs in arm 1, with anemia (14.5 vs. 2.7 %; p \ 0.05) and thrombocytopenia (23.3 vs. 5.6 %; p \ 0.05) higher in the pemetrexed arm, while grade 3/4 neutropenia occurred at a significantly higher rate in arm 2 (25.8 vs. 40.6 %; p \ 0.05). It is worth noting that these phase III trials were not specifically designed to evaluate bevacizumab's utility as a maintenance agent per se, and the drug's impact on PFS, OS, and QoL past induction with platinum doublet therapy remains an unanswered question.
Cetuximab, a chimeric monoclonal antibody against the extracellular portion of the epidermal growth factor receptor (EGFR), has been evaluated in conjunction with first-line doublet therapy in 2 phase III randomized trials. In the FLEX (First-Line ErbituX in lung cancer) trial, Pirker et al. [13] randomized NSCLC patients with EGFR as determined by IHC in an open-label fashion to cisplatin and vinorelbine every 3 weeks with or without weekly cetuximab (400 mg/m 2 i.v. loading dose for week 1, followed by 250 mg/m 2 thereafter) for up to 6 cycles, with continuation of cetuximab past induction until progression or toxicity with OS as the primary endpoint. There was a significant improvement in OS in the cetuximab group (11.3 vs. 10.1 months; HR 0.871; 95 % CI 0.762-0.996; p = 0.044), with 10 % of patients in the cetuximab arm developing a grade 3 or higher acneiform rash. Retrospective analysis revealed that median OS was higher in the cetuximab arm than in the control group (12.0 vs. 9.6 months; HR 0.73; p = 0.011) [36] . Additional retrospective analyses of biomarkers of interest (KRAS and EGFR mutation status, EGFR copy number, PTEN expression) were not predictive for efficacy in the cetuximab arm [37] .
Another phase III trial conducted by Lynch et al. [38] Table 3 ) that is currently enrolling utilizes carboplatin and paclitaxel (with the addition of bevacizumab per treating physician discretion) with randomization (1:1) to weekly cetuximab versus observation. EGFR expression by IHC is being collected from all patients upon enrollment for further biomarker analysis, based in part upon the encouraging OS results for patients with high EGFR IHC expression in the FLEX trial [36] . It is important to note that none of the aforementioned trials were designed to directly address whether the maintenance portion of the cetuximab therapy impacts PFS and OS. To date this agent is not approved for use in stage IIIB/IV NSCLC by the FDA or EMA. Additional prospective trials such as SWOG 0819 are needed with improved biomarker selection in order to determine if addition of cetuximab induction and maintenance lead to clinically meaningful outcomes for NSCLC patients. EGFR TKIs have also been investigated in 4 phase III trials in conjunction with conventional chemotherapy: two that used gefitinib [39, 40] and two that used erlotinib [41, 42] . Both of the INTACT (Iressa NSCLC Trial Assessing Combination Treatment) trials [39, 40] randomized NSCLC patients irrespective of EGFR mutation status to platinum-based doublet chemotherapy (cisplatin plus gemcitabine and carboplatin plus paclitaxel) plus either gefitinib at 500 mg/day, gefitinib 250 mg/day, or placebo. Both trials continued gefitinib until progression or unacceptable toxicity, and both failed to meet their primary endpoint of median OS (INTACT 1: 9.9, 9.9, 10.9 months and INTACT 2: 8.7, 9.8, and 9.9 months for gefitinib 500 mg/day, 250 mg/day, and placebo, respectively). The Tarceva Responses in Conjunction with Paclitaxel and Carboplatin (TRIBUTE) trial was the first phase III study to employ erlotinib in combination with first-line chemotherapy, randomizing NSCLC patients regardless of EGFR mutation status to 6 cycles of carboplatin/paclitaxel with either erlotinib at 150 mg/day or placebo followed by continuation of TKI until progression or unacceptable toxicity [42] . The trial failed to meet its primary endpoint of median OS, with final results nearly identical in the erlotinib (10.6 months) and placebo (10.5 months; p = 0.95) arms. Gatzemeier et al. [41] conducted the TALENT (Tarceva Lung Cancer Investigation) trial with comparator arms of gemcitabine plus cisplatin combined with either placebo or erlotinib at 150 mg/day for 6 cycles, with continuation of erlotinib until toxicity or disease progression. The primary endpoint of median OS was not met (43 weeks in the erlotinib arm vs. 44.1 in placebo; HR 1.06; 95 % CI 0.90-1.23; p = 0.49), with no significant difference observed in the secondary endpoints of TTP, ORR, or QoL. None of the aforementioned trials enrolled patients by EGFR mutation status; nor were they specifically designed to address the use of EGFR TKIs as continuation maintenance therapy. A full list of continuation maintenance trails which continue the non-platinum portion of the induction therapy is provided in Table 1 .
Switch Maintenance Therapy
Switch Maintenance: Conventional Chemotherapy
Switch maintenance therapy was recently addressed in a 2011 ASCO focused practice guideline update, where it was defined as an ''alternative therapy administered to patients who have undergone first-line therapy for a specified number of cycles'' [7] . Unlike second-line therapy, switch therapeutic agents are administered immediately after first-line chemotherapy in the absence of radiographic progression or demonstrated resistance to the first-line therapy. Phase III trials investigating switch maintenance have administered maintenance agents with non-overlapping mechanisms of action compared to the original drugs used as the first-line therapy under the principle that patients will not be cross-resistant and that they may avoid cumulative toxicity.
Phase III data for switch maintenance therapy were first reported by Westeel et al. [43] , who randomized 573 stage IIIB/IV patients to 2 monthly cycles of mitomycin, ifosfamide, and cisplatin (MIC) with subsequent thoracic radiotherapy for the IIIB cohort or 4 additional monthly cycles for stage IIIB (with malignant effusions) and stage IV NSCLC patients. One hundred eighty-one patients with responding or stable disease were then randomized to receive maintenance vinorelbine for 6 months or BSC with a primary endpoint of OS. Only 23 % of the patients were able to complete the planned 6 months of vinorelbine, with discontinuation due to progressive disease (38 %) and toxicity (21 %) being most common. The trial failed to meet its primary endpoint of median OS, with an identical OS of 12.3 months (p = 0.65) seen in both the vinorelbine and BSC groups; nor did it meet a secondary endpoint of improved PFS, with a median PFS of 5 months in the vinorelbine group vs. 3 months in the BSC group (p = 0.11).
Fidias et al. [44] conducted the first phase III trial employing switch maintenance using a modern platinumbased doublet chemotherapy, randomizing 309 patients with IIIB/IV NSCLC who had yet to progress on 4 cycles of gemcitabine (1, 
Additional post hoc analysis demonstrated an identical OS of 12.5 months in each cohort for those patients that received docetaxel chemotherapy, suggesting that the observed benefit of switch maintenance docetaxel was due to a higher likelihood of receiving second-line docetaxel prior to a decline in performance status or death. It is also worth noting that this remains the only trial that directly addresses the timing of second-line agents as either switch maintenance or early second-line therapies.
Recently, clinical trials addressing switch maintenance using third-generation cytotoxics have been reported. Ciuleanu et al. [45] published the first phase III trial using pemetrexed as a switch maintenance agent, in which stage IIIB/IV NSCLC patients with objective response or stable disease after the completion of 4 cycles of a platinumbased doublet of choice (either cisplatin or carboplatin paired with gemcitabine, paclitaxel, or docetaxel), irrespective of histology, were randomized to either pemetrexed at 500 mg/m 2 every 3 weeks until unacceptable toxicity or disease progression was observed or BSC, with vitamin B 12 , folic acid, and dexamethasone administered to both arms. The trial was powered for and met its primary endpoint of PFS, with a median PFS in the pemetrexed cohort of 4.3 vs. 2.6 months for BSC (HR 0.50; 95 % CI 0.42-0.61; p \ 0.0001). Median OS as a secondary endpoint was also significant, with 13.4 months in the pemetrexed cohort vs. 10.6 months in the BSC arm (HR 0.79; 95 % CI 0.65-0.95; p = 0.012). Toxicity was higher in the treatment group but was reported as manageable, with 16 % grade 3/4 events in pemetrexed vs. 4 % in BSC, the most common being fatigue (5 vs. 1 %) and [46] . Both the EMA and the FDA have approved pemetrexed as switch maintenance therapy for NSCLC patients with nonsquamous histology whose advanced or metastatic disease has not progressed after four cycles of first-line platinum-based chemotherapy.
Switch Maintenance: Targeted Agents
As agents that target specific molecular drivers of NSCLC, TKIs and monoclonal antibodies have an innate appeal for switch maintenance therapy. These agents often show few overlapping toxicities with conventional cytotoxic chemotherapy, and their use in switch maintenance has been investigated in several randomized controlled trials. Cappuzzo et al. [47] conducted the SATURN (Sequential Tarceva in Unresectable NSCLC) trial, which evaluated the efficacy of erlotinib as a switch maintenance agent in NSCLC patients. In this trial, 1949 enrolled NSCLC patients received 4 cycles of platinum-based chemotherapy as the first-line therapy. Patients with stable or responding disease (n = 889) following completion of the first-line therapy were randomized to erlotinib or placebo until progression or unacceptable toxicity. In addition to age, performance status, chemotherapy regimen, smoking history, and region, patents were stratified by EGFR IHC expression in order to address co-primary endpoints of PFS in the entire cohort and PFS in patients with high expression of EGFR by IHC. There was a modest improvement in median PFS in the erlotinib arm of 12.3 vs. . Toxicity was higher in the erlotinib arm, with rash and diarrhea of any grade in 60 and 20 % in the erlotinib arm vs. 9 and 5 % in the placebo arm. Grade 3/4 toxicity in the erlotinib arm versus placebo arm included rash (9 vs. 0 %) and diarrhea (2 vs. 0 %), with a serious adverse event rate of 11 % in the erlotinib arm vs. 8 % in the placebo arm, the most common being pneumonia (2 vs. \1 %). Lastly, there was no significant difference in time to deterioration of QoL between the two study arms. Given the statistically significant but modest clinical benefit in PFS and OS in this nonselected study cohort, erlotinib was approved by the FDA and the EMA for use in maintenance therapy for advanced NSCLC patients after stable or responsive disease with first-line platinum therapy. As expected, the PFS differences in the EGFR mutant cohort were dramatic, but the 1.2 week PFS difference in the nonselected cohort is of debatable clinical significance, and an informed discussion with EGFR wild-type patients regarding the absolute benefit and expected toxicity should occur prior to employing this maintenance strategy rather than switch maintenance or continuation maintenance with pemetrexed [28, 45] . As discussed in Sect. 2.1, Perol et al. [22] randomized advanced NSCLC patients with stable or responsive disease after 4 cycles of cisplatin and gemcitabine to daily maintenance erlotinib (150 mg/day) vs. gemcitabine vs. BSC. When possible, EGFR mutational analysis (n = 14) was performed and EGFR expression was investigated via IHC (n = 261) on tumor biopsy samples at enrollment. Median PFS was 2.9 months (erlotinib) vs. 1.9 months for BSC, and favored the erlotinib arm (HR 0.69; 95 % CI 0.54-0.88; p = 0.003). However, this PFS benefit did not translate to a statistically significant median OS survival benefit (11.4 vs. 10.8 months in erlotinib vs. BSC, respectively; HR 0.87; 95 % CI 0.68-1.13; p = 0.3043). EGFR IHC status had no statistically significant benefit for either EGFR-positive (HR 0.76; 95 % CI 0.49-1.18) or EGFR IHC-negative tumors (HR 0.77; 95 % CI 0.47-1.28). Survival analysis was not performed by the study on the EGFR mutation-positive cohort due to the small sample size.
The role of the EGFR TKI gefitinib has been investigated in 3 switch maintenance phase III trials with variable degrees of clinical impact. Takeda et al. [50] reported the final results of their West Japan Thoracic Oncology Group trial (WJTOG0203) where 604 advanced NSCLC patients were randomized after 3 cycles of a platinum doublet to gefitinib (250 mg/day) or up to 3 additional cycles of chemotherapy. While there was a statistically significant difference in median PFS in the gefitinib arm (4.6 vs. 4.3 months, HR 0.68; 95 % CI 0.57-0.80; p \ 0.001), this trial failed to meet its primary endpoint of OS (13.7 vs. 12.9 months; p = 0.11). Patients with EGFR-activating mutations were not assessed in this trial, as these mutations were yet to be established as a predictive biomarker for EGFR TKIs at the time of accrual.
Zhang et al. conducted the INFORM (Iressa in NSCLC FOR Maintenance) multicenter phase III trial, into which 296 patients across China with advanced NSCLC who had not progressed after 4 cycles of first-line platinum-based doublet chemotherapy were enrolled. Patients were randomized to gefitinib (250 mg/day) or placebo until disease progression or unacceptable toxicity [51] . While patients with a known EGFR mutation were excluded from the trial to avoid selection bias, EGFR mutation analysis was performed in 39 patients in the experimental arm and 40 patients in the placebo arm. The primary endpoint, PFS, was achieved with a median PFS of 4.8 months for gefitinib vs. 2.6 months for placebo (HR 0.42; 95 % CI 0.33-0.55; p \ 0.0001), with a greater benefit seen for the patients harboring an EGFR-activating mutation (16.6 vs. 2.8 months; HR 0.17; 95 % CI 0.07-0.42). Further subgroup analysis revealed that the benefit was restricted to the EGFR mutation-positive cohort, as EGFR wild-type patients had no difference in PFS (2.7 vs. 1.5 months; HR 0.86, 95 % CI 0.48-1.51; p = 0.0063). There was no statistically significant benefit in median OS amongst the entire treatment group (18.7 vs. 16.9 months; HR 0.84; 95 % CI 0.62-1.14; p = 0.26), in part due to inadequate power for this secondary endpoint, and also due to the higher proportion of patients in the placebo arm receiving second-line therapy compared to the gefitinib cohort (62 % in the placebo group, 29 % of whom received subsequent gefitinib vs. 43 % for the gefitinib arm). Median OS data for the EGFR mutation subgroup was not provided.
Lastly, Gaafar et al. [52] conducted the EORTC 08021/ILCP 01/03 trial, where advanced NSCLC patients with nonprogressive disease after four cycles of platinumbased chemotherapy were randomized to gefitinib (250 mg/day) vs. placebo. While the study planned to randomize 598 patients, only 173 patients were randomized, and the study was closed prematurely. As such, the study's primary endpoint, OS, was underpowered and not statistically different between the study groups (10.9 vs. 9.4 months for gefitinib and placebo, respectively; p = 0.204), with a statistically significant improvement in PFS in the gefitinib cohort of 4.1 vs. 2.9 months, respectively (HR 0.61; 95 % CI 0.45-0.83; p = 0.0015). Currently, data from these gefitinib switch maintenance trials do not provide adequate evidence to support its use in the maintenance setting, and gefitinib has yet to gain approval from major regulatory agencies for maintenance use.
Bevacizumab, a humanized monoclonal antibody against the VEGFA ligand evaluated by Miller et al. [53] via ATLAS (the Avastin and Tarceva in Lung Cancer Study), which was designed to study the efficacy of two different regimens-erlotinib plus bevacizumab versus bevacizumab alone-in a switch maintenance setting. This trial enrolled 1,160 patients with advanced non-squamous NSCLC (including patients who were anticoagulated with low molecular weight heparin and those with treated brain metastasis), to whom 4 cycles of bevacizumab were administered at 15 mg/kg every 3 weeks with a first-line platinum-based chemotherapy selected by the provider. Of these, 768 patients who had stable or responding disease after 4 cycles were randomized to continuation bevacizumab (B) or bevacizumab plus 150 mg/day of erlotinib (B ? E). The primary objective was detection of a PFS difference in the B ? E cohort over the B treatment group, with secondary outcomes of OS and safety assessments. The trial met its primary endpoint with a modest improvement in PFS of 4.8 months in the B ? E cohort vs. 3.7 months in the B cohort (HR 0.72; 95 % CI 0.59-0.88; p = 0.0012). However, this did not translate into a difference in median OS (15.9 vs. 13.9 months for B ? E and B, respectively; HR 0.91; 95 % CI 0.80-1.04; p = 0.27) with greater toxicity in the B ? E arm. Higher rates of rash (10.4 vs. 0.5 %) and diarrhea (9.3 vs. 0.8 %) were observed in the B ? E arm vs. the B arm, respectively. The number of patients who received additional post-study therapy was similar in each arm (55 % in B ? E vs. 50 % in B). This trial does not address the question of whether continuing bevacizumab past the first-line therapy confers an additional benefit, and its findings imply that the application of an additional targeted agent in the maintenance setting provided marginal benefit in PFS and no demonstrable OS benefit. However, an atypically high median OS time in the control cohort, coupled with the fact that the trial was stopped after the first interim analysis when it met its primary endpoint, limits the ability to detect a difference in OS. A summary of switch maintenance trials is supplied in Table 2 .
Meta-Analyses of Maintenance Trials
With the exception of a few selected trials [28, 45, 47] , most clinical trials that specifically address maintenance therapy in NSCLC demonstrate variable improvements in PFS over their control arms without a statistically significant improvement in OS. However, many of these trials were either not powered to detect a difference in OS, could not control for subsequent salvage therapies post-study, or both. Recently, several meta-analyses have attempted to broadly assess the impact of maintenance chemotherapy with second-and third-line chemotherapy agents with a primary endpoint of OS. Lima et al. [54] indirectly addressed the concept of continuation maintenance via a meta-analysis of 1,559 patients from 7 clinical trials in order to determine PFS and OS differences between trials with low (B4 cycles) and high (C4 cycles) numbers of fixed cycles vs. continuation of treatment until disease progression or unacceptable toxicity. The study was designed to investigate modern platinum-based doublet chemotherapy regimens, with one notable exception [55] , and excluded trials employing targeted agents. Treatment for longer than 4 cycles was not associated with a statistically significant difference in median OS (HR 0.97; 95 % CI 0.84-1.11; p = 0.65). Indeed, in trials using a thirdgeneration agent, there was a trend towards increased mortality for more than 4 cycles of chemotherapy (HR 1.08; 95 % CI 0.90-1.28; p = 0.28). Patients treated with more than 4 cycles of chemotherapy did have a significant improvement in median PFS (HR 0.75; 95 % CI 0.60-0.85; p \ 0.0001), but this was associated with a greater degree of hematological toxicity (odds ratio 1.31; 95 % CI 1.01-1.69; p = 0.04).
Maintenance was also addressed in a meta-analysis by Soon et al. [56] , where 13 randomized controlled trials with 3,027 patients that compared a fixed number of treatment cycles to continuation of therapy until progression/unacceptable toxicity were assessed. While extension of chemotherapy did improve PFS (HR 0.75; 95 % CI 0.69-0.81; p \ 0.00001), there was only a modest improvement in median OS (HR 0.92; 95 % CI 0.86-0.99; p = 0.03). There was a greater impact on PFS in trials using thirdgeneration chemotherapy regimens compared to older regimens (HR 0.7 vs. 0.92; p = 0.003), and the modest OS benefit observed only became statistically significant when the trial of switch maintenance pemetrexed was included [45] . Treatment-related adverse events were more pronounced in all trials using continuation therapy, and QoL endpoint results were variable, with two of the seven trials including QoL assessments reporting a net negative effect on QoL, with no detectable difference in QoL in the remaining trials.
Behera et al. [57] reported results of a meta-analysis evaluating 10 trials with 3,451 patients with single-agent continuation or switch maintenance after a fixed number of chemotherapy cycles. In aggregate, the median OS ( While all aforementioned trials included third-generation chemotherapy, only two of the meta-analyses included and evaluated the use of targeted therapies and EGFR TKIs as a specific subgroup. Behera et al. [57] Trials employing bevacizumab as a maintenance agent were included in the Behera and Zhang metaanalyses. It is notable that the recently released OS data from the PARAMOUNT trial were not available for inclusion in these meta-analyses, and these results could have had an effect on the above studies' OS results if available [28] .
Maintenance Therapy: Future Directions
There are several currently open multi-institution clinical trials that specifically address ongoing concerns with NSCLC maintenance therapy (Table 3) . Briefly, many of these trials are attempting to address open questions regarding the use of targeted therapy, with trial designs specifically addressing the role of bevacizumab as a maintenance agent, the role of cetuximab as a first-line and maintenance agent for NSCLC, and the use of third-generation and/or targeted agents with non-overlapping toxicities as dual maintenance therapy. Sunitinib, an oral multi-targeted TKI with antiangiogenic activity, is being investigated in CALGB 30607, a phase III trial that randomizes patients with non-progressive disease after four cycles of carboplatin plus paclitaxel to either oral sunitinib or placebo until progressive disease or unacceptable toxicity (NCT00693992). Previous open-label phase II experience with 66 patients demonstrated potential value with this approach, with an ORR of 27 %, although the study failed to meet its primary endpoint of overall survival at 1 year of C55 % (40.5 % in the study population) [59] .
In addition, several immune-and vaccine-based therapy strategies are being evaluated in NSCLC, with several phase III trials currently enrolling patients (Table 3) . This treatment approach challenges the current perception of 6 cells/injection) demonstrated a 2-year survival of 47 vs. 18 % in low-dose groups when the vaccine was administered monthly after first-line chemotherapy [62] . TG4010, an attenuated live-virus vaccine, is engineered for high expression of MUC1 and IL-2, and is currently enrolling to a phase III trial (NCT01383148). In an openlabel, randomized phase II trial, 148 patients with MUC1 tumor expression receiving subcutaneous TG4010 (weekly 9 6 weeks then q3 weeks until disease progression) after first-line cisplatin/gemcitabine had a 6-month PFS of 44 vs. 35 % (p = 0.13) and a higher ORR (44 vs. 27 %; p = 0.03) compared to control patients receiving first-line cisplatin/gemcitabine alone [63] . A recombinant human vaccine coupling human EGF to a carrier protein was evaluated in a phase II study [64] . Patients with advanced NSCLC (n = 80) were randomized to cyclophosphamide priming (200 mg/m 2 ) followed by vaccine (50 lg equivalents of EGF on days 1, 7, 14, and 28, followed by monthly injections until progression) versus BSC. There was a nonsignificant trend towards OS in the vaccinated group (6.5 vs. 5.3 months; p = 0.098), with patients\60 years of age demonstrating a larger and significant OS improvement (11.6 vs. 5.3 months; p = 0.124). This vaccine is currently being investigated in a phase II/III trial (NCT00516685). Given recent advances in early-phase trials with other active immunotherapy agents demonstrating clinical response, this will certainly be an active area of research for maintenance therapy in NSCLC [65, 66] .
Lastly, correct patient selection for maintenance therapy remains an active area of investigation, specifically with regards to the clinicopathologic and biologic heterogeneity of NSCLC. Pemetrexed, the only conventional chemotherapy agent with current FDA and EMA approval for maintenance therapy, has demonstrated differential efficacy in advanced nonsquamous histology [26] . Bevacizumab has been approved by the FDA for first-line use in advanced nonsquamous NSCLC only, given safety concerns in the squamous cohort during phase II trials, leaving no current maintenance chemotherapy options for patients with squamous cell carcinoma that have demonstrated improvements in OS and are approved for use by major regulatory agencies [29] . Given that several ongoing phase III trials (Table 3) exclude patients with squamous cell histology, a safe and effective maintenance therapy for this subgroup is an area of active need. While erlotinib is approved in the US and Europe, irrespective of histology for switch maintenance, the clinical benefit of this agent in squamous histology is questionable, with the SATURN study demonstrating a non-significant trend towards improvement in PFS in 360 patients with squamous histology (HR 0.76; 95 % CI 0.60-0.95; p [ 0.05) and OS (HR 0.86; 95 % CI 0.68-1.10; p [ 0.05) [47] .
Maintenance Therapy: Summary and Recommendations
Given the current data available, the authors agree with current ASCO guidelines regarding first-line therapy of NSCLC, and recent 2011 updates addressing maintenance therapy in particular [7] . Briefly, NSCLC patients whose disease is stable but not responding to first-line cytotoxic chemotherapy should have platinum chemotherapy discontinued after 4 cycles of treatment. Patients with responding disease who are tolerating initial combination cytotoxic chemotherapy may proceed with 6 cycles of platinum-based chemotherapy in total. Patients with ECOG PS B2 with stable or responsive disease after 4-6 cycles of chemotherapy should be considered for maintenance chemotherapy. For NSCLC patients with nonsquamous histology who are initially treated with pemetrexed as part of a platinum doublet, we believe that continuation of pemetrexed as a maintenance agent until progression or unacceptable toxicity is warranted, given recent updated data from the PARAMOUNT trial demonstrating a statistically significant difference in OS using this strategy. For patients with squamous histology or nonsquamous patients with a non-pemetrexed-containing first-line therapy, switch maintenance therapy with erlotinib or pemetrexed (in nonsquamous cohorts) may be considered. These patients must be selected carefully, providing an informed discussion of the use of immediate switch maintenance vs. early treatment at the time of progression. NSCLC patients who are found to harbor an EGFR-activating mutation following the initiation of first-line chemotherapy should consider switch maintenance erlotinib following a fixed number of cycles of chemotherapy, with the caveat that patients with EGFR mutations treated with pemetrexed-based chemotherapy may also benefit from the continuation of singleagent pemetrexed until disease progression or intolerance before switching to erlotinib. Patients with nonsquamous histology who are placed on bevacizumab as part of their first-line therapy should consider continuing this therapy up to a year after 4-6 cycles of their cytotoxic therapy if this agent is well tolerated, with the caveat that it is unknown if bevacizumab's benefit occurs during induction chemotherapy alone, during the maintenance phase, or both. In general, the recent availability of new chemotherapy (pemetrexed), TKIs, and immunotherapy agents with a more tolerable or nonoverlapping toxicity profile have enabled maintenance strategies to be successful, and this approach should be considered in patients responding to first-line therapy when possible.
